Literature DB >> 21788451

The critical need for alternative antiretroviral formulations, and obstacles to their development.

Susan Swindells1, Charles Flexner, Courtney V Fletcher, Jeffrey M Jacobson.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21788451      PMCID： PMC3156101          DOI： 10.1093/infdis/jir370

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  24 in total

1.  Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000).

Authors: 
Journal:  HIV Clin Trials       Date:  2001 Jan-Feb

2.  A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.

Authors:  Jennifer King; Matthew McCall; Anthony Cannella; Michael Anne Markiewicz; Amanda James; Chantelle B Hood; Edward P Acosta
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

3.  Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Authors:  Ari S Nowacek; JoEllyn McMillan; Reagan Miller; Alec Anderson; Barrett Rabinow; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-17       Impact factor: 4.147

4.  Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-04-17

Review 5.  Interventions for treating oral mucositis for patients with cancer receiving treatment.

Authors:  Jan E Clarkson; Helen V Worthington; Susan Furness; Martin McCabe; Tasneem Khalid; Stefan Meyer
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

6.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

7.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

8.  Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.

Authors:  Jeffrey M Jacobson; Daniel R Kuritzkes; Eliot Godofsky; Edwin DeJesus; Jeffrey A Larson; Steven P Weinheimer; Stanley T Lewis
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

9.  Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

Authors:  Gerben van 't Klooster; Eva Hoeben; Herman Borghys; Adriana Looszova; Marie-Paule Bouche; Frans van Velsen; Lieven Baert
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240
View more
  18 in total

1.  Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.

Authors:  Rachna Aneja; Antonella Grigoletto; Aakansha Nangarlia; Adel A Rashad; Steven Wrenn; Jeffrey M Jacobson; Gianfranco Pasut; Irwin Chaiken
Journal:  J Pept Sci       Date:  2019-02-27       Impact factor: 1.905

Review 2.  Implementation challenges for long-acting antivirals as treatment.

Authors:  Diane Havlir; Monica Gandhi
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

3.  Liposomes as nanocarriers for anti-HIV therapy.

Authors:  Shruti Chopra; Natarajan Venkatesan; Guru V Betageri
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

4.  Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

Authors:  Upal Roy; JoEllyn McMillan; Yazen Alnouti; Nagsen Gautum; Nathan Smith; Shantanu Balkundi; Prasanta Dash; Santhi Gorantla; Andrea Martinez-Skinner; Jane Meza; Georgette Kanmogne; Susan Swindells; Samuel M Cohen; R Lee Mosley; Larisa Poluektova; Howard E Gendelman
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  The clinical role and cost-effectiveness of long-acting antiretroviral therapy.

Authors:  Eric L Ross; Milton C Weinstein; Bruce R Schackman; Paul E Sax; A David Paltiel; Rochelle P Walensky; Kenneth A Freedberg; Elena Losina
Journal:  Clin Infect Dis       Date:  2015-01-12       Impact factor: 9.079

Review 6.  Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.

Authors:  Jeffrey M Jacobson; Charles W Flexner
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

7.  Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

Authors:  Jennifer Williams; Harlan R Sayles; Jane L Meza; Patrick Sayre; Uriel Sandkovsky; Howard E Gendelman; Charles Flexner; Susan Swindells
Journal:  Nanomedicine (Lond)       Date:  2013-04-23       Impact factor: 5.307

8.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

9.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

10.  Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.

Authors:  Adel A Rashad; Ramalingam Venkat Kalyana Sundaram; Rachna Aneja; Caitlin Duffy; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.